Zevra Therapeutics Inc
ZVRA11.250USD
+0.140+1.26%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
615.14MValor de mercado
PerdaP/L TTM
Mais detalhes de Zevra Therapeutics Inc Empresa
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.
Informações da empresa
Código da empresaZVRA
Nome da EmpresaZevra Therapeutics Inc
Data de listagemApr 16, 2015
CEOMr. Neil F. Mcfarlane
Número de funcionários59
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 16
Endereço1180 Celebration Boulevard
CidadeCELEBRATION
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal34747
Telefone13219393416
Sitehttps://zevra.com/
Código da empresaZVRA
Data de listagemApr 16, 2015
CEOMr. Neil F. Mcfarlane
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Neil F. Mcfarlane
Mr. Neil F. Mcfarlane
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
191.52K
+35.33%
Mr. John B. Bode
Mr. John B. Bode
Independent Director
Independent Director
40.00K
--
Mr. Joshua Schafer
Mr. Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Executive Vice President - Business Development, Chief Commercial Officer
28.33K
-27.04%
Dr. Wendy L. Dixon, Ph.D.
Dr. Wendy L. Dixon, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Thomas D. (Tom) Anderson
Mr. Thomas D. (Tom) Anderson
Independent Director
Independent Director
--
--
Mr. R. LaDuane Clifton, CPA
Mr. R. LaDuane Clifton, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Alvin Shih, M.D.
Dr. Alvin Shih, M.D.
Independent Director
Independent Director
--
--
Dr. Adrian Quartel, M.D.
Dr. Adrian Quartel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Corey Watton
Mr. Corey Watton
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Neil F. Mcfarlane
Mr. Neil F. Mcfarlane
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
191.52K
+35.33%
Mr. John B. Bode
Mr. John B. Bode
Independent Director
Independent Director
40.00K
--
Mr. Joshua Schafer
Mr. Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Executive Vice President - Business Development, Chief Commercial Officer
28.33K
-27.04%
Dr. Wendy L. Dixon, Ph.D.
Dr. Wendy L. Dixon, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Thomas D. (Tom) Anderson
Mr. Thomas D. (Tom) Anderson
Independent Director
Independent Director
--
--
Mr. R. LaDuane Clifton, CPA
Mr. R. LaDuane Clifton, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Detalhamento da receita
FY2024
FY2023
FY2022
FY2021
FY2020
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
23.61M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Woodline Partners LP
8.44%
BlackRock Institutional Trust Company, N.A.
6.92%
Adage Capital Management, L.P.
6.62%
The Vanguard Group, Inc.
5.17%
Fidelity Management & Research Company LLC
4.00%
Other
68.85%
Investidores
Investidores
Proporção
Woodline Partners LP
8.44%
BlackRock Institutional Trust Company, N.A.
6.92%
Adage Capital Management, L.P.
6.62%
The Vanguard Group, Inc.
5.17%
Fidelity Management & Research Company LLC
4.00%
Other
68.85%
Tipos de investidores
Investidores
Proporção
Hedge Fund
24.22%
Investment Advisor
22.55%
Investment Advisor/Hedge Fund
14.58%
Research Firm
1.43%
Private Equity
1.25%
Individual Investor
0.71%
Venture Capital
0.33%
Bank and Trust
0.11%
Pension Fund
0.06%
Other
34.76%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
239
35.69M
65.27%
-2.27M
2025Q1
252
39.54M
72.42%
-1.74M
2024Q4
247
37.53M
70.32%
+3.07M
2024Q3
232
32.67M
61.46%
+11.34M
2024Q2
214
19.77M
45.38%
+395.88K
2024Q1
213
17.66M
40.45%
-265.50K
2023Q4
207
16.32M
37.86%
+175.17K
2023Q3
203
14.77M
38.14%
-620.11K
2023Q2
208
12.57M
36.97%
-1.13M
2023Q1
207
10.52M
30.95%
-2.74M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Woodline Partners LP
4.62M
8.44%
+476.03K
+11.50%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.78M
6.92%
+18.09K
+0.48%
Mar 31, 2025
Adage Capital Management, L.P.
3.62M
6.62%
-32.00K
-0.88%
Mar 31, 2025
The Vanguard Group, Inc.
2.83M
5.17%
+1.63K
+0.06%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.19M
4%
-15.70K
-0.71%
Mar 31, 2025
Nantahala Capital Management, LLC
1.47M
2.69%
-868.40K
-37.11%
Mar 31, 2025
Altium Capital Management LP
1.29M
2.35%
-562.67K
-30.41%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.23M
2.26%
+44.99K
+3.79%
Mar 31, 2025
683 Capital Management LLC
1.23M
2.24%
--
--
Mar 31, 2025
Rubric Capital Management LP
1.22M
2.23%
+601.61K
+97.64%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Simplify Propel Opportunities ETF
1.92%
iShares Neuroscience and Healthcare ETF
1.17%
SPDR S&P Pharmaceuticals ETF
0.49%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.35%
iShares Micro-Cap ETF
0.11%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
Vanguard US Momentum Factor ETF
0.04%
iShares Russell 2000 Growth ETF
0.03%
Ver Mais
Simplify Propel Opportunities ETF
Proporção1.92%
iShares Neuroscience and Healthcare ETF
Proporção1.17%
SPDR S&P Pharmaceuticals ETF
Proporção0.49%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção0.35%
iShares Micro-Cap ETF
Proporção0.11%
Invesco Nasdaq Biotechnology ETF
Proporção0.05%
iShares Biotechnology ETF
Proporção0.05%
ProShares Ultra Nasdaq Biotechnology
Proporção0.05%
Vanguard US Momentum Factor ETF
Proporção0.04%
iShares Russell 2000 Growth ETF
Proporção0.03%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
